felin
caliciviru
fcv
small
nonenvelop
viru
contain
singlestrand
positivesens
rna
genom
approxim
kb
fcv
highli
infecti
pathogen
cat
typic
caus
moder
selflimit
acut
oral
upper
respiratori
tract
diseas
chronic
oral
diseas
addit
recent
year
virul
system
fcv
vsfcv
strain
caus
sever
system
diseas
high
mortal
rate
report
cat
although
fcv
vaccin
commerci
avail
efficaci
limit
due
antigen
divers
fcv
strain
short
durat
immun
studi
identifi
fexaramin
potent
inhibitor
fcv
includ
vsfcv
strain
cell
cultur
demonstr
fexaramin
entri
blocker
fcv
use
variou
experi
includ
timeofaddit
studi
gener
resist
virus
cell
cultur
revers
genet
system
fexaramin
resist
fcv
mutant
singl
amino
acid
chang
domain
major
capsid
import
mutat
confer
resist
confirm
use
revers
genet
system
compar
analysi
viral
resist
also
perform
use
peptidyl
inhibitor
target
fcv
proteas
final
effect
combin
treatment
fexaramin
fcv
replic
emerg
resist
virus
investig
cell
cultur
felin
caliciviru
fcv
small
nonenvelop
viru
contain
positivesens
singlestrand
rna
genom
approxim
kb
clark
et
al
fcv
belong
calicivirida
famili
virus
includ
import
pathogen
human
anim
norovirus
sapovirus
vesicular
exanthema
swine
viru
rabbit
hemorrhag
diseas
viru
green
pesavento
et
al
least
six
genera
calicivirida
noroviru
sapoviru
vesiviru
lagoviru
neboviru
recoviru
clark
et
al
genera
noroviru
sapoviru
contain
human
calicivirus
major
caus
viral
gastroenter
green
fcv
belong
genu
vesiviru
highli
import
infecti
pathogen
cat
fcv
caus
acut
selflimit
oral
upper
respiratori
tract
diseas
lame
chronic
infect
also
occur
often
recent
year
virul
system
fcv
vsfcv
strain
caus
sever
system
diseas
high
mortal
report
us
eu
foley
et
al
pesavento
et
al
fcv
vaccin
avail
cat
antigen
divers
fcv
strain
shortliv
immun
limit
efficaci
vaccin
addit
symptomat
nonsymptomat
carrier
pose
continu
challeng
control
fcv
infect
therefor
develop
effect
therapeut
agent
variou
fcv
strain
expect
provid
signific
benefit
manag
control
fcv
infect
cat
fcv
genom
three
open
read
frame
orf
pesavento
et
al
viral
polyprotein
consist
nonstructur
protein
viral
proteas
viral
polymeras
produc
process
function
matur
protein
capsid
precursor
translat
subsequ
cleav
viral
major
capsid
protein
leader
protein
capsid
sosnovtsev
et
al
encod
minor
structur
protein
interact
form
capsid
associ
rna
genom
packag
sosnovtsev
et
al
fcv
capsid
compos
copi
copi
prasad
et
al
sosnovtsev
green
compos
subdomain
pesavento
et
al
sosnovtsev
et
al
subdomain
involv
antigen
receptor
interact
bhella
goodfellow
ossiboff
et
al
process
cell
entri
fcv
nonenvelop
viru
gener
well
understood
viral
bind
cellular
receptor
believ
trigger
conform
chang
capsid
lead
capsid
disassembl
releas
content
replic
bhella
et
al
johnson
recent
viru
entri
becom
one
target
therapeut
intervent
small
molecul
inhibitor
target
viru
capsid
report
nonenvelop
virus
includ
picornavirus
buontempo
et
al
de
palma
et
al
ho
et
al
kim
et
al
et
al
romero
thi
et
al
tijsma
et
al
torrestorr
et
al
present
studi
identifi
fexaramin
highli
effect
inhibitor
fcv
cell
cultur
determin
fexaramin
synthet
agonist
farnesoid
x
receptor
fxr
function
entri
blocker
use
variou
vitro
assay
identifi
mutat
confer
viral
resist
fexaramin
cell
cultur
addit
effect
combin
treatment
fexaramin
inhibitor
previous
report
group
kim
et
al
prior
et
al
replic
fcv
emerg
viral
resist
investig
crandellre
felin
kidney
cell
crfk
felin
infecti
periton
viru
fipv
strain
felin
coronaviru
purchas
american
type
cultur
collect
manassa
va
nonvsfcv
strain
includ
urbana
vsfcv
strain
includ
jengo
deuc
kind
gift
dr
green
nation
institut
health
sosnovtsev
green
dr
parker
cornel
univers
ossiboff
parker
fcv
fipv
propag
eagl
minim
essenti
medium
mem
supplement
fetal
bovin
serum
uml
penicillin
streptomycin
crfk
cell
fexaramin
purchas
sigmaaldrich
st
loui
mo
dissolv
dmso
mm
synthesi
proteas
inhibitor
previous
report
group
hyperimmun
guinea
pig
serum
rais
fcv
previous
describ
sosnovtsev
green
monoclon
antibodi
purchas
santa
cruz
biotechnolog
santa
cruz
ca
determin
effect
concentr
ec
fexaramin
fcv
threedayold
confluent
crfk
cell
plate
cell
per
well
respect
inocul
fcv
multipl
infect
moi
viru
infect
cell
incub
presenc
fexaramin
variou
concentr
day
compound
also
test
fipv
previous
report
strong
antivir
effect
fipv
fcv
kim
et
al
infect
cell
freezethaw
three
time
viru
titer
determin
standard
tcid
method
dilut
sampl
reed
muench
ec
compound
calcul
nonlinear
regress
analys
dosedepend
curv
viru
titer
log
inhibitor
concentr
variabl
slope
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
least
independ
sampl
use
determin
ec
valu
confluent
crfk
cell
grown
plate
incub
fexaramin
variou
concentr
day
cell
cytotox
measur
cytotox
nonradioact
cytotox
assay
kit
promega
madison
wi
dayincub
cytotox
concentr
cc
fexaramin
determin
use
graphpad
prism
invitro
therapeut
indic
cc
ec
also
calcul
viru
strain
confluent
crfk
cell
mocktreat
treat
variou
concentr
fexaramin
immedi
infect
fcv
urbana
strain
moi
follow
incub
h
cell
lyse
sdspage
sampl
buffer
contain
protein
resolv
novex
trisbi
gel
invitrogen
carlsbad
ca
transfer
nitrocellulos
membran
viral
protein
probe
use
fcv
antibodi
dilut
sosnovtsev
green
peroxidaseconjug
goat
antiguinea
pig
igg
follow
incub
chemiluminesc
substrat
dilut
pierc
biotechnolog
rockford
il
chemiluminesc
signal
detect
use
fotodyn
transilluminatordigit
camera
system
fotodynefx
hartland
wi
use
load
control
timeofaddit
studi
fexaramin
cell
cultur
confluent
crfk
cell
wash
pb
infect
fcv
urbana
strain
moi
h
cell
wash
pb
three
time
remov
residu
virus
fexaramin
ad
cell
h
preinfect
h
postinfect
cell
incub
presenc
compound
h
postinfect
cell
freez
thaw
three
time
viru
titer
determin
tcid
method
reed
muench
separ
experi
confluent
crfk
cell
preincub
fexaramin
h
wash
pb
prior
viru
infect
cell
incub
without
compound
h
viral
replic
evalu
describ
sequenti
cell
cultur
passag
fcv
urbana
strain
perform
presenc
fexaramin
gener
resist
virus
synthesi
antivir
effect
inhibitor
previous
report
group
fcv
resist
determin
crfk
cell
infect
fcv
moi
presenc
fexaramin
concentr
near
ec
valu
passag
supernat
contain
virus
pass
fresh
cell
presenc
increas
concentr
fexaramin
altern
cell
infect
fcv
moi
presenc
fexaramin
supernat
passag
concentr
compound
control
fcv
urbana
wt
fcv
viru
passag
absenc
compound
follow
procedur
viru
titer
select
passag
number
determin
tcid
assay
fold
chang
ec
valu
rel
wt
fcv
determin
total
viral
rna
isol
use
rneasi
mini
kit
invitrogen
passag
number
fexaramin
full
length
fcv
genom
sequenc
follow
amplif
rtpcr
identif
mutat
construct
infecti
clone
carri
singl
amino
acid
mutat
identifi
fexaramineresist
fcv
mutat
introduc
gene
urbana
strainbas
infecti
clone
sosnovtsev
green
sitedirect
mutagenesi
result
clone
design
anoth
infecti
clone
carri
singl
amino
acid
mutat
identifi
fcv
also
gener
introduc
mutat
clone
primer
sequenc
analysi
vitro
mutagenesi
list
tabl
wt
mutant
clone
verifi
sequenc
analysi
test
replic
capabl
previous
describ
briefli
oneday
old
semiconflu
crfk
cell
infect
vaccinia
viru
encod
polymeras
h
wash
pb
ad
fresh
medium
plasmid
transfect
cell
use
lipofectamin
accord
manufactur
protocol
follow
incub
cell
h
cell
supernat
transfer
monolay
crfk
cell
cell
incub
observ
daili
appear
cytopath
effect
cpe
h
recov
wt
mutant
fcv
cap
pro
examin
amino
acid
chang
genom
sequenc
analysi
wt
mutant
fcv
growth
kinet
ec
valu
fexaramin
determin
describ
threedimension
structur
fcv
gener
pymol
http
wwwpymolorg
use
pdb
id
delano
threedimension
structur
fcv
built
easymodel
softwar
use
rhinoviru
polioviru
human
noroviru
hepat
viru
pdb
id
respect
templat
previous
describ
kim
et
al
first
combin
treatment
fexaramin
conduct
determin
whether
synergist
antagonist
addit
effect
fcv
replic
fcv
urbana
strain
inocul
confluent
crfk
cell
moi
h
medium
replac
mockmedium
medium
contain
fexaramin
combin
fexaramin
variou
concentr
infect
cell
incub
h
viru
titer
determin
tcid
assay
drugdrug
interact
data
analyz
confid
level
use
macsynergi
ii
softwar
suhnel
first
theoret
addit
interact
calcul
doserespons
curv
compound
calcul
addit
surfac
subtract
experiment
determin
doserespons
surfac
yield
region
synergist
antagonist
interact
result
horizont
plane
interact
two
compound
addit
synergi
synergi
antagon
shown
peak
horizont
plane
respect
tabl
primer
use
sequenc
analysi
mutagenesi
studi
sequenc
separ
experi
effect
combin
treatment
fexaramin
emerg
viral
resist
compound
determin
procedur
use
gener
resist
virus
follow
sequenti
cell
cultur
passag
fcv
urbana
strain
conduct
presenc
fexaramin
viru
titer
select
passag
number
determin
tcid
assay
fold
chang
ec
valu
fexaramin
rel
wt
fcv
calcul
viru
passag
student
ttest
use
compar
signific
unpair
sampl
mean
p
valu
consid
signific
structur
fexaramin
shown
fig
fexaramin
inhibit
replic
nonvsfcv
vsfcv
strain
ec
valu
rang
tabl
cc
valu
fexaramin
crfk
cell
determin
tabl
calcul
invitro
therapeut
indic
cc
ec
fexaramin
rang
fcv
rang
fcv
fip
show
signific
antivir
effect
fexaramin
littl
effect
replic
fipv
tabl
previous
report
strong
broadspectrum
antivir
effect
fcv
fipv
kim
et
al
tabl
antivir
effect
fexaramin
fcv
urbana
strain
confirm
western
blot
analysi
show
signific
reduct
compound
dosedepend
manner
fig
dosedepend
inhibit
fexaramin
fcv
urbana
determin
viral
titrat
tcid
shown
fig
timeofaddit
studi
show
signific
viral
inhibit
occur
fexaramin
ad
cell
cultur
prior
viru
infect
h
within
h
postinfect
pi
h
pi
fig
block
cleavag
newli
produc
viral
polyprotein
inhibit
viru
replic
ad
h
pi
fig
preincub
crfk
cell
fexaramin
h
prior
viru
infect
littl
effect
viru
replic
data
shown
result
show
fexaramin
work
viru
entri
step
viru
replic
occur
fcv
resist
fexaramin
gener
passag
fcv
urbana
strain
presenc
compound
crfk
cell
fold
increas
ec
valu
serial
passag
virus
compar
wt
fcv
shown
fig
rapid
emerg
fexaramineresist
viru
observ
increas
ec
valu
howev
contrast
fexaramin
virus
appear
later
passag
increas
ec
valu
fig
analysi
fullgenom
sequenc
virus
resist
fexaramin
led
identif
singl
amino
acid
substitut
gene
respect
substitut
fcv
locat
subdomain
fig
alanin
amino
acid
posit
highli
conserv
among
fcv
sequenc
report
genbank
strain
compris
fcv
sequenc
follow
valin
prolin
fig
howev
none
fcv
sequenc
report
threonin
posit
substitut
fcv
locat
ctermin
domain
near
activ
site
fig
threonin
residu
posit
conserv
report
fcv
sequenc
strain
use
revers
genet
system
fcv
cap
recombin
fcv
mutat
pro
recombin
fcv
mutat
gener
growth
kinet
cap
pro
compar
wt
fcv
fig
indic
replic
effici
mutant
fcv
compromis
mutat
ec
valu
cap
fexaramin
pro
increas
compar
wt
fcv
fig
respect
fold
increas
compar
observ
resist
virus
gener
serial
passag
fig
expect
cap
pro
retain
suscept
fexaramin
respect
cell
cultur
fig
virusinfect
cell
treat
combin
fexaramin
synergist
effect
observ
maxim
synergi
concentr
fig
b
synergi
volum
determin
confid
interv
log
volum
cytotox
observ
concentr
combin
treatment
emerg
resist
virus
fexaramin
observ
kim
ko
chang
antivir
research
sequenti
cell
cultur
passag
fcv
combin
treatment
fexaramin
fexaramin
synthet
agonist
farnesoid
x
receptor
fxr
member
nuclear
receptor
famili
play
import
role
metabol
pathway
lipid
glucos
metabol
down
et
al
effect
fxr
modul
metabol
increas
energi
expenditur
food
intak
suggest
potenti
use
fexaramin
treatment
obes
metabol
syndrom
insulin
resist
fang
et
al
effect
fxr
agonist
lipid
metabol
also
shown
play
role
replic
virus
requir
close
interact
lipid
content
honk
et
al
radreau
et
al
previous
report
fxr
agonist
includ
bile
acid
fexaramin
inhibit
replic
rotaviru
inhibitori
effect
mediat
reduct
cellular
lipid
content
activ
fxr
studi
demonstr
replic
fcv
potent
inhibit
fexaramin
cell
cultur
interestingli
investig
mode
fcv
inhibit
fexaramin
variou
experi
includ
timeofaddit
studi
analysi
viral
resist
show
contrast
inhibit
rotaviru
fexaramin
act
entri
inhibitor
fcv
viru
entri
inhibitor
develop
report
envelop
virus
includ
human
immunodefici
viru
hiv
haqqani
tilton
woollard
kanmogn
influenza
viru
pales
shaw
measl
viru
plemper
et
al
dengu
viru
scaturro
et
al
viru
entri
inhibitor
also
report
nonenvelop
virus
includ
picornavirus
includ
polioviru
thi
et
al
enteroviru
buontempo
et
al
ho
et
al
et
al
torrestorr
et
al
rhinovirus
kim
et
al
tijsma
et
al
howev
entri
inhibitor
caliciviru
report
first
report
small
molecul
entri
inhibitor
felin
caliciviru
also
test
fexaramin
murin
noroviru
porcin
enter
caliciviru
sapoviru
preliminari
studi
minim
inhibitori
activ
cell
cultur
virus
data
shown
studi
differ
field
strain
fcv
includ
vsfcv
strain
caus
agent
fatal
system
infect
among
cat
suscept
antivir
effect
fexaramin
cell
cultur
although
potent
found
antivir
effect
fexaramin
fcv
slightli
less
inhibitor
fcv
cell
cultur
kim
et
al
note
fexaramin
low
genet
barrier
resist
fexaramineresist
virus
readili
obtain
within
serial
passag
fig
contrast
case
fcv
virus
obtain
later
viral
passag
decreas
drug
suscept
less
magnitud
compar
fexaramin
fig
analysi
fexaramineresist
fcv
show
singl
mutat
confer
viral
resist
fexaramin
alanin
site
subdomain
locat
surfaceexpos
loop
subdomain
highli
conserv
among
fcv
field
strain
fig
mutat
fexaramineresist
viru
sit
adjac
mutat
previous
identifi
fcv
mutant
confer
resist
solubl
ectodomain
fcv
receptor
ossiboff
et
al
felin
function
adhes
molecul
fjama
makino
et
al
ossiboff
parker
analysi
resist
mutant
gener
solubl
fjama
suggest
bind
fcv
fjam
lead
conform
chang
fcv
ossiboff
et
al
bind
subsequ
conform
chang
seem
mediat
residu
locat
surfaceexpos
hidden
region
includ
subdomain
respect
ossiboff
et
al
nonenvelop
virus
human
rhinovirus
hrv
report
undergo
conform
chang
viru
capsid
viru
entri
inhibit
capsid
conform
chang
small
molecul
inhibitor
report
hrv
enterovirus
pleconaril
entri
inhibitor
bind
hydrophob
pocket
hrv
induc
conform
chang
lead
alter
receptor
bind
viral
uncoat
romero
although
investig
specif
mechan
underli
inhibit
fexaramin
studi
plausibl
fexaramin
interact
residu
subdomain
fcv
interfer
viral
receptor
bind
andor
uncoat
viru
entri
plan
conduct
cocrystal
fcv
fcv
fexaramin
complex
understand
inhibitori
mechan
may
gener
valuabl
inform
potenti
optim
fexaramin
improv
antivir
effect
also
found
mutat
fcv
confer
resist
locat
activ
site
enzym
fig
threonin
posit
conserv
among
fcv
strain
correspond
threonin
posit
human
noroviru
viru
proteas
structur
function
close
relat
fcv
previou
crystallograph
studi
complex
human
noroviru
proteas
inhibitor
show
threonin
posit
form
hydrogen
bond
inhibitor
share
core
structur
takahashi
et
al
interestingli
growth
kinet
mutant
fcv
carri
compar
wt
fcv
suggest
combin
antivir
agent
differ
viral
target
use
reduc
risk
viral
resist
improv
efficaci
human
immunodefici
viru
hepat
c
viru
infect
asselah
et
al
pirron
et
al
therefor
studi
effect
combin
treatment
fexaramin
cell
cultur
found
combin
treatment
show
synergist
antivir
effect
test
drug
concentr
fig
importantli
combin
treatment
substanti
delay
emerg
resist
virus
fexaramin
passag
result
provid
strong
rational
investig
combin
treatment
antivir
agent
target
differ
viru
protein
overcom
resist
singl
antivir
agent
enhanc
antivir
activ
fcv
infect
conclus
studi
report
first
entri
inhibitor
fcv
potenti
combin
use
entri
inhibitor
viral
proteas
inhibitor
fcv
infect
fig
effect
combin
treatment
fexaramin
replic
fcv
cell
cultur
confluent
crfk
cell
infect
fcv
urbana
strain
medium
replac
fresh
medium
contain
mock
combin
fexaramin
cell
incub
h
viru
replic
measur
tcid
assay
b
drugdrug
interact
analyz
macsynergi
ii
softwar
confid
limit
color
indic
level
synergi
anatogon
peak
plane
synergi
plot
indic
synergi
interpret
refer
color
figur
legend
reader
refer
web
version
articl
